NICE ‘no’ for Opdivo, could deny some lung cancer patients one of the most significant advances in almost 20 years
The draft decision specifically affects adult patients with locally advanced or metastatic squamous non-small cell lung whose disease has progressed after prior chemotherapy.
Bristol-Myers Squibb (BMS0 has announced that the National Institute for Health and Care Excellence (NICE) has issued draft guidance for consultation that could prevent NHS patients with a form of lung cancer, from receiving Opdivo (nivolumab). The draft decision specifically affects adult patients with locally advanced or metastatic squamous non-small cell lung (NSCLC) whose disease has progressed after prior chemotherapy. In a pivotal clinical study, treatment with nivolumab was shown to achieve significantly superior survival rates, with 42% of patients still alive at one year compared with 24% of those treated with docetaxel. If this becomes final guidance, it will mean that treatment options for these patients will remain limited to chemotherapies, such as docetaxel which was first approved for use 17 years ago. Lung cancer is one of the UK’s biggest health challenges, with survival rates that lag almost a decade behind some European countries.
Johanna Mercier, General Manager, Bristol-Myers Squibb UK & Ireland, said: “Today’s draft decision is deeply disappointing for lung cancer patients and for us as we have worked extensively with the UK Health Authorities to enable prompt patient access to nivolumab. We have made this pioneering medicine available both through our clinical trial programme and through the Early Access to Medicines Scheme. We are continuing to work with NICE to facilitate access for patients who urgently need it.”
Nivolumab is the first in a new class of medicines, called PD-1 immune checkpoint inhibitors, to be licensed for use in squamous pre-treated lung cancer patients. It has an innovative mode of action that works by harnessing the ability of the immune system to find and fight cancer.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance